Amorfix Life Sciences Ltd. And Biogen Idec, Inc. (Massachusetts) To Collaborate On Research For ALS Disease; Upfront Payment And Potential Milestone Payments In Excess Of US$25 Million

Published: Aug 03, 2006

TORONTO, Aug. 3 /CNW/ - Amorfix Life Sciences Ltd. (TSXV: AMF), an emerging Canadian theranostics company, announced today that it has entered into a research and investment agreement with Biogen Idec (NASDAQ: BIIB) of Cambridge, Massachusetts, which includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). Amorfix will conduct a planned research program with operational support and investment from Biogen Idec.

>>> Discuss This Story

Back to news